Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Pål-Andre Holme"'
Autor:
Jan Astermark, Fariba Baghaei, Karin Strandberg, Petra Gabric Toplican, Maj Friberg Birkedal, Emma Engman Grahn, Charlotta Hansson, Peter Kampmann, Anna-Elina Lehtinen, Kinga Täckström, Pål Andre Holme, Maria Magnusson
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: Despite improvements in hemophilia care, challenges remain, including treatment burden and impaired quality of life. Gene therapy may overcome these. However, its introduction presents a challenge. Objectives: To outline a function-based
Externí odkaz:
https://doaj.org/article/0aa66564770c45379d3d4469b3bab69c
Autor:
Ellen M. K. Warlo MD, Vibeke Bratseth MSc, PhD, Alf-Åge R. Pettersen MD, PhD, Pål Andre Holme MD, PhD, Harald Arnesen MD, PhD, Ingebjørg Seljeflot PhD, Trine B. Opstad MSc, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
Introduction ADAMTS13 cleaves von Willebrand factor (VWF) multimers into less active fragments. Both markers have been related to cardiovascular disease (CVD). We aimed to investigate the influence of ADAMTS13 single nucleotide polymorphisms (SNPs) o
Externí odkaz:
https://doaj.org/article/d93a0d96222140258f2385432a148c0b
Autor:
Christian Qvigstad, R. Campbell Tait, Philippe deMoerloose, Pål Andre Holme, On behalf of the ADVANCE Working Group
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 2, Pp 309-317 (2020)
Abstract Introduction Macroscopic hematuria is considered a significant risk factor for urologic disease, and it is highly prevalent in people with hemophilia. Aim To determine whether prophylactic factor replacement therapy is associated with reduce
Externí odkaz:
https://doaj.org/article/3be73a5323e249469cfa9f5ae973e425
Autor:
Nina Haagenrud Schultz, Pål Andre Holme, Stine Bjørnsen, Carola Elisabeth Henriksson, Per Morten Sandset, Eva-Marie Jacobsen
Publikováno v:
Platelets, Vol 31, Iss 1, Pp 43-47 (2020)
Factor Xa inhibitors are safe and effective alternatives to warfarin, but several studies indicate that rivaroxaban may cause a different risk profile for bleeding. For instance, while the risk of major bleeding in general may be lower with rivaroxab
Externí odkaz:
https://doaj.org/article/06d2a660183045189d5073ccaf09412f
Autor:
Markus Wiedmann, Thor Skattør, Arne Stray-Pedersen, Luis Romundstad, Ellen-Ann Antal, Pål Bache Marthinsen, Ingvild Hausberg Sørvoll, Siw Leiknes Ernstsen, Christian G. Lund, Pål Andre Holme, Tonje Okkenhaug Johansen, Cathrine Brunborg, Anne Hege Aamodt, Nina Haagenrud Schultz, Karolina Skagen, Mona Skjelland
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
During a 2-week period, we have encountered five cases presenting with the combination of cerebral venous thrombosis (CVT), intracerebral hemorrhage and thrombocytopenia. A clinical hallmark was the rapid and severe progression of disease in spite of
Externí odkaz:
https://doaj.org/article/c3587c6c0a5e466a99a915d46b05b264
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Abstract Background Emicizumab is a nonfactor replacement therapy for hemophilia A (HA) and is a bispecific monoclonal antibody mimicking factor VIII by binding both factors IXa and X. Although it reduces the frequency of bleeding episodes, there is
Externí odkaz:
https://doaj.org/article/79b73affbc374ae49b6af79c4ec9592d
Autor:
Geir Hetland, Magne Kristoffer Fagerhol, Markus Karl Hermann Wiedmann, Arne Vasli Lund Søraas, Mohammad Reza Mirlashari, Lise Sofie Haug Nissen-Meyer, Mette Stausland Istre, Pål Andre Holme, Nina Haagenrud Schultz
Publikováno v:
Vaccines, Vol 10, Iss 8, p 1267 (2022)
ChAdOx1 nCoV-19 vaccination has been associated with the rare side effect; vaccine-induced immune thrombotic thrombocytopenia (VITT). The mechanism of thrombosis in VITT is associated with high levels of neutrophil extracellular traps (NETs). The pre
Externí odkaz:
https://doaj.org/article/a958bebb01884c628f0a35e7dda624e8
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Factor (F) Xa inhibitors are safe and effective alternatives to warfarin. There are concerns about the lack of a reversal strategy in case of serious bleeds or need for emergency surgery in situations when the antidote andexanet alfa is not available
Externí odkaz:
https://doaj.org/article/95711c6afc094cf08491e6e6a03d341f
Publikováno v:
Journal of Medical Case Reports, Vol 12, Iss 1, Pp 1-5 (2018)
Abstract Background The lack of an antidote against factor Xa inhibitors in case of major bleeding or need for urgent surgery is a concern to clinicians. Guidelines on managing major bleeding in patients under anticoagulation with a factor Xa inhibit
Externí odkaz:
https://doaj.org/article/06579b78a9444673a6aca1dc17d9aecb
Autor:
Robert Klamroth, Cihan Ay, Philippe De Moerloose, Pierre Fontana, Jerzy Windyga, Jan Astermark, Erik Berntorp, Manuela Carvalho, Gerard Dolan, Cedric Hermans, Pål Andre Holme, Gili Kenet, Maria Elisa Mancuso, Natascha Marquardt, Ramiro Nunez, Ingrid Pabinger, Ryan Rodgers, Paul van der Valk, Victor Jimenez Yuste, Irena Preložnik Zupan
Publikováno v:
Haemophilia, Vol. 29, no.1, p. 21-32 (2023)
INTRODUCTION: As people with haemophilia (PWH) receive better treatment and live longer they are more likely to encounter cardiovascular disease (CVD) and other comorbidities. ESC guidelines for the acute management of patients presenting with acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09d40da51ab75a0f88b347e9bc0ab4e4
https://doi.org/10.1111/hae.14674
https://doi.org/10.1111/hae.14674